Evidence map›Paper›PMID 41586900›Full record

ReviewCellular and molecular life sciences : CMLS2026

The role of HMGA1 in genome stability: Implications in human cancer.

Xin-Yuan Lei, Kai-Yue He, Yong-Ping Jian, Zhi-Xiang Xu

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xin-Yuan LeiSchool of Life Sciences, Henan University, Kaifeng, Henan, China.
Kai-Yue HeSchool of Life Sciences, Henan University, Kaifeng, Henan, China.
Yong-Ping JianSchool of Life Sciences, Henan University, Kaifeng, Henan, China. yongpingjian123@163.com.
Zhi-Xiang XuSchool of Life Sciences, Henan University, Kaifeng, Henan, China. zhixiangxu08@gmail.com.ORCID http://orcid.org/0000-0002-2385-3044

Funding

he National Natural Science Foundation of China 82020108024, 82200596, and 82400658Postdoctoral Science Foundation of Jiangsu Province 2022M721014the National Key Research and Development Program of China 2023YFE0109800
6 · The paper itself

Abstract

High mobility group A1 (HMGA1), a non-histone chromatin structural protein encoded by the HMGA1 gene, plays a critical role in cancer. Recent studies have increasingly focused on its functions in genomic stability and cell death, revealing its involvement in tumorigenesis, cancer progression, and chemotherapy resistance. Consequently, inhibiting HMGA1 represents a promising strategy for developing novel cancer therapies. This review summarizes the cellular and molecular functions of HMGA1 in regulating genomic integrity and cell death in cancer. Furthermore, we discuss current HMGA1-targeting strategies, with emphasis on approaches leveraging its structural and functional characteristics, aiming to provide new insights for future research on HMGA1-targeted cancer therapies.

Indexed as

Genomic InstabilityHMGA1a ProteinNeoplasmsAnimalsHumansHMGA1a ProteinHMGA1 protein, humanCancerCell deathGenome stabilityHMGA1Targeted therapy

Identifiers

PMID41586900
PMCPMC12852536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.